KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Profit After Tax (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Profit After Tax for 7 consecutive years, with $214.2 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax fell 68.5% to $214.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 20.66% year-over-year, with the annual reading at $770.9 million for FY2025, 42.07% down from the prior year.
  • Profit After Tax hit $214.2 million in Q4 2025 for Royalty Pharma, down from $444.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $806.8 million in Q2 2021 to a low of -$797.3 million in Q4 2022.
  • Historically, Profit After Tax has averaged $234.6 million across 5 years, with a median of $221.1 million in 2021.
  • Biggest five-year swings in Profit After Tax: tumbled 1585.46% in 2022 and later soared 10243.53% in 2025.
  • Year by year, Profit After Tax stood at $53.7 million in 2021, then crashed by 1585.46% to -$797.3 million in 2022, then soared by 162.0% to $494.3 million in 2023, then surged by 37.57% to $680.0 million in 2024, then crashed by 68.5% to $214.2 million in 2025.
  • Business Quant data shows Profit After Tax for RPRX at $214.2 million in Q4 2025, $444.2 million in Q3 2025, and $30.2 million in Q2 2025.